Diabetic Ketoacidosis News and Research

RSS

Diabetic ketoacidosis – (DKA) or diabetic coma occurs when a diabetic does not properly balance their insulin intake with their diet or activity.

FDA approves first non-insulin drug for treatment of pediatric patients with type 2 diabetes

The U.S. Food and Drug Administration today approved Victoza (liraglutide) injection for treatment of pediatric patients 10 years or older with type 2 diabetes.

18 Jun 2019

Type 1 diabetes symptoms are not recognized early enough among children in Quebec

Elwyn was a healthy 13 month-old toddler when she started drinking water from the bathtub. Over time, she became increasingly thirsty and demanded more and more breast milk.

14 May 2019

Diabetes complications rise sharply in the U.S. as teenagers transition to adulthood, but not in Canada

Hospitalizations for a feared complication of diabetes, diabetic ketoacidosis, rise sharply as adolescents transition to adulthood in the U.S, but not in Canada, according to a new study published May 8 in the Journal of General Internal Medicine. DKA can generally be prevented with regular use of insulin.

8 May 2019

Gestational diabetes during pregnancy may increase risk of type 1 diabetes in children

Children of mothers who had gestational diabetes during pregnancy could be at increased risk of type 1 diabetes themselves, according to a new study led by a team at the Research Institute of the McGill University Health Centre that was published in the Canadian Medical Association Journal.

16 Apr 2019

FDA authorizes new interoperable insulin pump for children, adults with diabetes

The U.S. Food and Drug Administration today permitted marketing of the Tandem Diabetes Care t:Slim X2 insulin pump with interoperable technology (interoperable t:Slim X2) for delivering insulin under the skin for children and adults with diabetes.

15 Feb 2019

New diabetes drugs linked to increased risk of lower-limb amputation and ketoacidosis

The use of a new class of drugs in the treatment of type 2 diabetes, so called SGLT2 inhibitors, are linked to a twofold increased risk for lower-limb amputation as well as diabetic ketoacidosis, a serious diabetes complication.

14 Nov 2018

Diabetes medication reduces risk of heart failure hospitalization

In the largest trial to date to assess cardiovascular outcomes for an important class of diabetes medications, researchers have found that dapagliflozin markedly reduced the risk of hospitalization for heart failure in a broad population of patients with diabetes.

12 Nov 2018

AstraZeneca to present Phase III CVOT DECLARE-TIMI 58 results at AHA Scientific Sessions

AstraZeneca will present 20 abstracts including a late-breaking oral presentation on the full results from the Phase III cardiovascular outcomes trial DECLARE -TIMI 58, the broadest SGLT2 inhibitor CVOT conducted to date, as well as new research from the Company's Cardiovascular, Renal & Metabolism therapy area at the American Heart Association Scientific Sessions, November 10-12, 2018, in Chicago, Illinois, USA.

1 Nov 2018

Merck presents MK-1454 Phase 1 data for treatment of advanced solid tumors or lymphomas

Merck, known as MSD outside the United States and Canada, today announced the first presentation of preliminary data from a Phase 1 clinical trial evaluating MK-1454, an investigational STING (stimulator of interferon genes) agonist, as monotherapy and in combination with KEYTRUDA (pembrolizumab), Merck's anti-PD-1 therapy, in patients with advanced solid tumors or lymphomas.

22 Oct 2018

Merck presents KEYNOTE-057 trial results for patients with high-risk non-muscle invasive bladder cancer

Merck, known as MSD outside the United States and Canada, today announced the first presentation of results from an interim analysis of KEYNOTE-057, a Phase 2 trial evaluating KEYTRUDA, Merck's anti-PD-1 therapy, for previously treated patients with high-risk non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ or CIS plus papillary disease (Cohort A).

22 Oct 2018

New pragmatic study launched to understand the effectiveness of new type 2 diabetes drug

HealthCore, Inc., the outcomes research subsidiary of Anthem, Inc. and Novo Nordisk Inc., which manufacturers the once weekly GLP-1 receptor agonist Ozempic (semaglutide), are working together to launch the first of its kind pragmatic study to understand the benefits of semaglutide as compared with all other available diabetes drugs in a real-world pragmatic clinical trial for Type 2 diabetes - one of the nation's fastest growing chronic diseases.

17 Oct 2018

Closed-loop insulin delivery system shows better results for blood sugar control in type 1 diabetes

New research presented at this year's annual meeting of the European Association for the Study of Diabetes in Berlin, Germany, and published in The Lancet, shows that use of a hybrid day-night closed-loop insulin delivery system is better than sensor-augmented pump therapy for blood sugar control in poorly controlled type 1 diabetes.

3 Oct 2018

Pfizer announces FDA approval of VIZIMPRO for first-line treatment of EGFR-mutated metastatic NSCLC

Pfizer Inc. today announced that the U.S. Food and Drug Administration has approved VIZIMPRO [vih-ZIM-pro] (dacomitinib), a kinase inhibitor for the first-line treatment of patients with metastatic non-small cell lung cancer with epidermal growth factor receptor exon 19 deletion or exon 21 L858R substitution mutations as detected by an FDA-approved test.

28 Sep 2018

Diabetic Ketoacidosis News and Research

Further Reading

FDA approves first non-insulin drug for treatment of pediatric patients with type 2 diabetes

Type 1 diabetes symptoms are not recognized early enough among children in Quebec

Diabetes complications rise sharply in the U.S. as teenagers transition to adulthood, but not in Canada

Gestational diabetes during pregnancy may increase risk of type 1 diabetes in children

FDA authorizes new interoperable insulin pump for children, adults with diabetes

New diabetes drugs linked to increased risk of lower-limb amputation and ketoacidosis

Diabetes medication reduces risk of heart failure hospitalization

AstraZeneca to present Phase III CVOT DECLARE-TIMI 58 results at AHA Scientific Sessions

Merck presents MK-1454 Phase 1 data for treatment of advanced solid tumors or lymphomas

Merck presents KEYNOTE-057 trial results for patients with high-risk non-muscle invasive bladder cancer

New pragmatic study launched to understand the effectiveness of new type 2 diabetes drug

Closed-loop insulin delivery system shows better results for blood sugar control in type 1 diabetes

Pfizer announces FDA approval of VIZIMPRO for first-line treatment of EGFR-mutated metastatic NSCLC

FARXIGA receives positive results in Phase III DECLARE-TIMI 58 cardiovascular outcomes trial

Insulin’s high cost leads to deadly rationing

Scientists demonstrate how medical test results can be remotely modified

UCI research team uncovers new unexpected mode of neurotransmitter-based communication

Very low carbohydrate diet may improve blood sugar control in type 1 diabetes

Very-low-carb diets found to improve blood sugar control in type 1 diabetes

Advanced insulin pump system can also manage type 1 diabetes in children, study shows

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News